JP2021500864A5 - - Google Patents

Download PDF

Info

Publication number
JP2021500864A5
JP2021500864A5 JP2020517500A JP2020517500A JP2021500864A5 JP 2021500864 A5 JP2021500864 A5 JP 2021500864A5 JP 2020517500 A JP2020517500 A JP 2020517500A JP 2020517500 A JP2020517500 A JP 2020517500A JP 2021500864 A5 JP2021500864 A5 JP 2021500864A5
Authority
JP
Japan
Prior art keywords
composition
seq
guide
ttr
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020517500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021500864A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/053382 external-priority patent/WO2019067872A1/en
Publication of JP2021500864A publication Critical patent/JP2021500864A/ja
Publication of JP2021500864A5 publication Critical patent/JP2021500864A5/ja
Priority to JP2022194564A priority Critical patent/JP7707140B2/ja
Priority to JP2025112164A priority patent/JP2025163016A/ja
Pending legal-status Critical Current

Links

JP2020517500A 2017-09-29 2018-09-28 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法 Pending JP2021500864A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022194564A JP7707140B2 (ja) 2017-09-29 2022-12-06 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法
JP2025112164A JP2025163016A (ja) 2017-09-29 2025-07-02 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762566236P 2017-09-29 2017-09-29
US62/566,236 2017-09-29
US201862671902P 2018-05-15 2018-05-15
US62/671,902 2018-05-15
PCT/US2018/053382 WO2019067872A1 (en) 2017-09-29 2018-09-28 COMPOSITIONS AND METHODS FOR EDITING THE TTR GENE AND TREATING AMYLOID DOSE ATTR

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022194564A Division JP7707140B2 (ja) 2017-09-29 2022-12-06 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法

Publications (2)

Publication Number Publication Date
JP2021500864A JP2021500864A (ja) 2021-01-14
JP2021500864A5 true JP2021500864A5 (enExample) 2021-11-04

Family

ID=63858214

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020517500A Pending JP2021500864A (ja) 2017-09-29 2018-09-28 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法
JP2022194564A Active JP7707140B2 (ja) 2017-09-29 2022-12-06 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法
JP2025112164A Pending JP2025163016A (ja) 2017-09-29 2025-07-02 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022194564A Active JP7707140B2 (ja) 2017-09-29 2022-12-06 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法
JP2025112164A Pending JP2025163016A (ja) 2017-09-29 2025-07-02 Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法

Country Status (16)

Country Link
US (4) US20200248180A1 (enExample)
EP (1) EP3688161A1 (enExample)
JP (3) JP2021500864A (enExample)
KR (1) KR20200058509A (enExample)
CN (2) CN111417728A (enExample)
AU (2) AU2018338787C1 (enExample)
BR (1) BR112020005287A2 (enExample)
CA (1) CA3077251A1 (enExample)
CO (1) CO2020005116A2 (enExample)
IL (3) IL311170B2 (enExample)
MX (2) MX2020003608A (enExample)
MY (1) MY203849A (enExample)
PH (1) PH12020550364A1 (enExample)
SG (1) SG11202002565YA (enExample)
TW (1) TWI904069B (enExample)
WO (1) WO2019067872A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
MX2021011690A (es) * 2019-03-28 2022-01-06 Intellia Therapeutics Inc Composiciones y métodos para la edición del gen ttr y el tratamiento de la amiloidosis attr que comprende un corticosteroide o uso de este.
MX2021011757A (es) * 2019-03-28 2021-12-10 Intellia Therapeutics Inc Polinucleótidos, composiciones y métodos para la expresión de polipéptidos.
KR20220004648A (ko) * 2019-03-28 2022-01-11 인텔리아 테라퓨틱스, 인크. Ttr 가이드 rna, 및 rna-가이드 dna 결합제를 암호화하는 폴리뉴클레오티드를 포함하는 조성물 및 방법
WO2020247452A1 (en) * 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
AU2020401206A1 (en) * 2019-12-11 2022-07-14 Intellia Therapeutics, Inc. Modified guide RNAs for gene editing
WO2022094152A1 (en) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anti-transthyretin antibodies and methods of use thereof
EP4259792A1 (en) 2020-12-11 2023-10-18 Intellia Therapeutics, Inc. Polynucleotides, compositions, and methods for genome editing involving deamination
CN112795595A (zh) * 2020-12-24 2021-05-14 中山大学 一种遗传性转甲状腺素蛋白淀粉样变性疾病的基因治疗系统
CA3220738A1 (en) * 2021-05-21 2022-11-24 Beam Therapeutics Inc. Base editing of transthyretin gene
WO2022271780A1 (en) 2021-06-22 2022-12-29 Intellia Therapeutics, Inc. Methods for in vivo editing of a liver gene
WO2023028469A2 (en) * 2021-08-23 2023-03-02 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells
JP2024535888A (ja) 2021-09-20 2024-10-02 アルナイラム ファーマシューティカルズ, インコーポレイテッド インヒビンサブユニットベータe(inhbe)モジュレーター組成物およびその使用方法
CN116064598B (zh) * 2021-10-08 2024-03-12 苏州艾博生物科技有限公司 冠状病毒的核酸疫苗
CN118974256A (zh) * 2022-03-29 2024-11-15 锐正基因(苏州)有限公司 用于治疗转甲状腺素蛋白淀粉样变性的组合物和方法
WO2024003805A1 (en) * 2022-06-30 2024-01-04 Geneditbio Limited Methods and compositions for ttr gene editing and therapy using crispr system
WO2024003810A1 (en) * 2022-06-30 2024-01-04 Geneditbio Limited Guide rna with chemical modifications
CN118853659A (zh) * 2023-04-14 2024-10-29 深圳瑞吉生物科技有限公司 提高mRNA翻译蛋白的输出量的核酸及其应用
EP4728093A1 (en) 2023-06-13 2026-04-22 Intellia Therapeutics, Inc. Assays for analysis of ribonucleic acid (rna) molecules
KR20260094824A (ko) * 2023-10-25 2026-06-23 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 고효율, 저오프타겟 유전자 편집 도구
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026149586A1 (en) * 2025-01-13 2026-07-16 Geneditbio Limited Compositions comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent and methods using the same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
WO2006007712A1 (en) 2004-07-19 2006-01-26 Protiva Biotherapeutics, Inc. Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents
EP2323667A4 (en) 2008-08-07 2012-07-25 Isis Pharmaceuticals Inc MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
JP5723378B2 (ja) 2009-11-03 2015-05-27 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. トランスサイレチン(ttr)を阻害する脂質製剤化組成物及び方法
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
UA118649C2 (uk) 2011-11-18 2019-02-25 Елнілем Фармасьютікалз, Інк. ДВОЛАНЦЮГОВИЙ ЗАСІБ ДЛЯ PHKі ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ТРАНСТИРЕТИНУ (TTR)
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
SG10201707569YA (en) * 2012-12-12 2017-10-30 Broad Inst Inc Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
SG11201510327TA (en) * 2013-06-17 2016-01-28 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
WO2015183026A1 (ko) * 2014-05-28 2015-12-03 주식회사 툴젠 불활성화된 표적 특이적 뉴클레아제를 이용한 표적 dna의 분리 방법
DK3161128T3 (en) * 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
US10369232B2 (en) * 2015-09-21 2019-08-06 Arcturus Therapeutics, Inc. Allele selective gene editing and uses thereof
DK4276189T3 (da) 2015-09-21 2026-05-26 Trilink Biotechnologies Llc Initierende oligonukleotidprimere med kappe til syntesering af 5'-ende RNA'er med kappe
US11866727B2 (en) * 2015-11-06 2024-01-09 Crispr Therapeutics Ag Materials and methods for treatment of glycogen storage disease type 1A
WO2017093804A2 (en) * 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
US11083799B2 (en) * 2016-03-16 2021-08-10 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
ES3030658T3 (en) * 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
WO2018007871A1 (en) * 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas

Similar Documents

Publication Publication Date Title
JP2023029966A5 (enExample)
JP2020501582A5 (enExample)
US20250034555A1 (en) High efficiency library-identified aav vectors
US12163124B2 (en) Method for gene editing
US20240271131A1 (en) Chemically modified single-stranded rna-editing oligonucleotides
JP7276422B2 (ja) 人工的に操作された血管新生調節系
US11459557B2 (en) Use and production of CHD8+/− transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
US20210180031A1 (en) Recombinant aavs having useful transcytosis properties
IL311170A (en) Compositions and methods for ttr gene editing and treating attr amyloidosis
EP4004207A1 (en) Oligonucleotide antagonists for rna guided genome editing
CN118064566A (zh) p55gamma蛋白或其编码基因作为靶点在制备预防和/或治疗血管钙化药物中的应用
CN119032176A (zh) 用于治疗血管生成素样3 (angptl3)相关状况的方法和组合物
CN119546758A (zh) 治疗、改善和/或预防多囊肾病和多囊肝病的方法
JP2020528735A (ja) 反復伸長変異のためのゲノム編集システム
Wood et al. Development of NTLA-2001, a CRISPR/Cas9 genome editing therapeutic for the treatment of ATTR.
CN121079409A (zh) Pah调节性系统和方法
WO2026008077A1 (en) Modified grna for gene editing using crispr/cas system
US20250367128A1 (en) Biodegradable lipidoids and compositions and methods of use thereof for liver targeted delivery
WO2026008078A1 (en) Methods for kallikrein (klkb1) gene editing
WO2025110249A1 (ja) 塩基配列編集用組成物およびそれを使用する塩基配列編集方法
WO2025128134A1 (en) Crispri targeting alpha-synuclein
Jarrett et al. Basic Sciences
CN121793975A (zh) 用于缓解与胆汁酸相关性肝病相关症状的手段和方法
NZ762942B2 (en) Compositions and methods for ttr gene editing and treating attr amyloidosis